

Serial No. 08/

--MRL--.

~~Page 24~~, line 14, (corresponding to page 31, line 13 of its English version), amend "immersed in a solution" to read --brought into contact with a solution--.

~~Page 32~~, lines 10-11 (corresponding to page 42, lines 25-27 of its English version), amend "According to the present invention, there are still further provided mutants of the monoclonal antibodies or active fragments thereof set forth in the above Items 6-10." as follows:

--According to the present invention, there are still further provided mutants of the above respective monoclonal antibodies or active fragments thereof. The term "Mutant" as used herein is used in a sense generally used in this technical field and specifically means one having an amino acid sequence in which one to several amino acids have been deleted, substituted or inserted in its corresponding amino acid sequence set forth in each SEQ ID NO., and maintaining the function (apoptosis inhibition function) of the monoclonal antibodies or the active fragments thereof.--

~~Page 32~~, lines 20-21 (corresponding to page 43, line 3 of its English version), amend "A mutant of a monoclonal antibody" to read --A monoclonal antibody--.

~~Page 33~~, lines 3-4 (corresponding to page 43, line 17 of its English version), amend "A mutant of a monoclonal antibody" to read --A monoclonal antibody--.

Serial No. 08/

Page 33, line 5 (of the English version), amend "ATTC" to
--ATCC--.

Page 63, lines 12-13 (corresponding to page 44, line 4 of its
English version), amend "A mutant of a monoclonal antibody" to read
--A monoclonal antibody--.

Page 68, line 7 (of the English version), amend "NOK3" to
--NOK1--.

Page 70, line 25 (of the English version), amend " $\mu\text{g}/\mu\text{l}$ " to
-- $\mu\text{g}/\text{ml}$ --.

Page 73, line 22 (of the English version), amend " cm^3 " to
-- cm^2 --.

IN THE CLAIMS:

Cancel claims 1-~~56~~⁵⁰.

Add claims 1-104 as they appear on the attached 25 sheets.